Ubrelvy (ubrogepant) / Merck (MSD), AbbVie - LARVOL DELTA

Systemic administration of CGRP receptor antagonist alleviates neuropathic spontaneous pain in mice (Neuroscience 2026) - "Together, these findings identify CGRP signaling as a critical contributor to spontaneous pain after peripheral nerve injury and support further mechanistic studies. Clinically approved CGRP receptor antagonists (gepants; e.g., rimegepant, atogepant, ubrogepant, zavegepant) may therefore represent a promising therapeutic strategy for peripheral nerve injury-induced spontaneous pain."

Preclinical • CNS Disorders • Migraine • Pain

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Chronic Migraine Remission with Combination of Remote Electrical Neuromodulation (REN) and In-Clinic / Patient-Administered Sphenopalatine Ganglion (SPG) Block (PAINWeek 2026) - "Current acute treatments included rizatriptan, ubrogepant and acetaminophen with recent discontinued acute therapies including rimegepant and NSAIDS. Current preventative treatments include onabotulinumtoxinA, galcanezumab, amitriptyline, cyclobenzaprine, ondansetron and occipital nerve blocks with recent discontinued preventatives including topiramate... Patient was seen weekly for initial treatment sequence and noted near complete resolution of acute migraine symptoms after the first in-clinic SPG administration with smaller, although noticeable, levels of relief with self-administered SPG administration. Patient also noted significant, although not complete, reduction of acute pain and nausea within the first week of initiating REN. After one month of treatment, patient noted that migraine frequency reduced to one episode per week from the previous 4 to 6 episodes and was able to manage most acute episodes with acetaminophen, with rare need for other acute..."

Clinical • CNS Disorders • Depression • Migraine

Asymmetric Synthesis of Chiral δ-Caprolactams: Access to a Key Intermediate of Ubrogepant. (PubMed, J Org Chem) - "Chiral δ-caprolactam constitutes the key pharmacophore of Calcitonin gene-related peptide receptor antagonists such as ubrogepant and atogepant, and its synthesis is quite challenging. The δ-caprolactam scaffold is first constructed via a one-pot process, followed by sequential installation of three stereocenters through crystallization-induced dynamic kinetic resolution and catalytic hydrogenation. This protocol offers distinct advantages, including the absence of enzymatic catalysis and column chromatography."

Journal

UBRO MM: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (clinicaltrials.gov) - P3 | N=496 | Active, not recruiting | Sponsor: AbbVie | Trial primary completion date: Jun 2027 ➔ Nov 2027

Adverse events • Trial primary completion date • CNS Disorders • Migraine

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

UBRELVY Recommended for Reimbursement by Canada's Drug Agency for Acute Migraine Treatment (Investing News Network (INN)) - "The recommendation is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies, which studied pain freedom, pain relief and freedom from the most bothersome migraine-associated symptoms....The CDA-AMC recommendation was informed by input from Canadian clinicians and patient organizations, including Migraine Canada, Migraine Québec and the Canadian Migraine Society, ensuring the perspectives of people living with migraine were considered throughout the review process."

Reimbursement • Migraine

Global net revenues from the neuroscience portfolio were $3.228 billion, an increase of 20.3 percent on a reported basis, or 19.8 percent on an operational basis. (PRNewswire) - "Global Ubrelvy net revenues were $392 million, an increase of 16.0 percent on a reported basis, or 15.9 percent on an operational basis; Global Qulipta net revenues were $350 million, an increase of 30.9 percent on a reported basis, or 30.3 percent on an operational basis; Global Vyalev net revenues were $256 million."

Sales • Dystonia • Migraine • Parkinson's Disease

Ubrelvy: Data from P3 UBRO MM trial (NCT06417775) for menstrual migraine prevention in 2026 (AbbVie) - Q2 2026 Results

P3 data • CNS Disorders • Migraine

Ubrelvy: Regulatory submission and approval in US for menstrual migraine prevention in 2027 (AbbVie) - Q2 2026 Results

FDA approval • FDA filing • CNS Disorders • Migraine

UBRO MM: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (clinicaltrials.gov) - P3 | N=496 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • CNS Disorders • Migraine

Efficacy, safety, and tolerability of ubrogepant in the treatment of acute migraine among migraine patients in Hail City, Saudi Arabia: A retrospective case. (PubMed, J Family Med Prim Care) - "Ubrogepant 100 mg was effective and well-tolerated for acute migraine treatment, with most patients experiencing pain relief and improved function within 2 hours. Most reported no side effects, supporting its use as a safe treatment option for acute migraine."

Journal • Retrospective data • CNS Disorders • Fatigue • Migraine • Pain

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. (PubMed, Headache) - "Commercial launch was the most consistent driver of public search interest in CGRP-targeting therapies. Media exposure produced additional increases in selected cases, whereas regulatory approvals and clinical trial publications had limited measurable impact. These findings underscore the dominant role of commercial and consumer-facing communication in shaping public awareness of new migraine treatments."

Journal • CNS Disorders • Migraine • Pain

Digital milestones and public interest in CGRP-targeting migraine therapies: An infodemiology study in the United States (AHS 2026) - "Seven FDA-approved preventive therapies were analyzed: erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, and ubrogepant. In the United States, commercial launches and targeted media exposure are the dominant drivers of public interest in CGRP-targeting therapies, while regulatory approvals and trial publications have limited impact. These findings highlight outsized influence of market entry and consumer-facing media on awareness of CGRP-targeting therapies, underscoring opportunities to strengthen communication around scientific and regulatory milestones. Public search interest in CGRP-therapies in the United States (2017–2025)."

CNS Disorders • Migraine • Pain

Early Wearing-Off of Onabotulinumtoxin A in Chronic Migraine: A Retrospective Study (EAN 2026) - "Ubrogepant was also more commonly used in the wearing-off group (33.4% vs. 6.2%, p = 0.000). Wearing-off was associated with higher baseline migraine frequency, earlier reinjection intervals, and increased use of acute therapies, suggesting that this subgroup may require tailored management strategies, including reassessing injection technique, dose optimization, shorter injection intervals (10 weeks), GON blocks inter procedures, optimizing other preventive treatment or using Gepants to improve outcomes."

Retrospective data • CNS Disorders • Migraine

TRPM7/M7CK-UHRF1 axis drives dna methylation-mediated senescence escape to promote oxaliplatin resistance in colorectal cancer (IDDF 2026) - "Conclusions This study unveils a novel signaling cascade wherein TRPM7 cleavage generates M7CK, which phosphorylates UHRF1 at Ser500 to enhance DNMT1 recruitment, driving epigenetic silencing of senescence genes and oxaliplatin resistance. Targeting this axis with MK-1602 represents a promising therapeutic strategy to overcome chemoresistance in CRC.Download figure Open in new tab Download powerpoint Abstract IDDF2026-ABS-0299 Figure 1"

Epigenetic controller • Colorectal Cancer • Oncology • Solid Tumor • CDKN1A • CDKN2A • DNMT1 • TRPM7 • UHRF1

Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada (clinicaltrials.gov) - P=N/A | N=178 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Real-world evidence • Trial completion • CNS Disorders • Migraine

“The Canadian Drug Expert Committee (CDEC) recommends that ubrogepant be reimbursed for the acute treatment of migraine…“ (Ottawa (ON): Canadian Agency for Drugs and Technologies in Health)

Reimbursement • CNS Disorders • Migraine • Pain

Migrainous Thoracalgia in a Patient with Chronic Migraine and Coronary Vasospasm: A Case Report. (PubMed, Int Med Case Rep J) - "Her CP partially responded to nitroglycerin and improved modestly with migraine control using ubrogepant and calcium channel blockers. During admission for refractory migraine, she received intravenous lidocaine, magnesium, ketorolac, and neuroleptics, resulting in several months of CP remission despite brief migraine relief. Longitudinal follow-up demonstrated that eptinezumab was associated with improvement in both migraine and CP symptoms...The observed improvement in CP following migraine-directed therapies raises the possibility of a shared neurovascular mechanism, although causality cannot be established. Greater awareness of MT and interdisciplinary management may improve outcomes in similar patients."

Journal • CNS Disorders • Coronary Artery Disease • Migraine • Pain

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Safety and tolerability of anti-PACAP monoclonal antibody Lu AG09222 when co-administered with a gepant in participants with migraine (AHS 2026) - "Lu AG09222 was well tolerated when co-administered with ubrogepant and did not alter ubrogepant pharmacokinetics. These data, together with similar results for co-administration with triptans presented previously, support the safety profile of Lu AG09222 for co administration with common acute migraine therapies."

Clinical • CNS Disorders • Migraine • Pain • ADCYAP1

Laughing before the storm: A case of gelastic migraine (AHS 2026) - "One Sentence Summary: We report a case of gelastic migraine in a 43-year-old woman with acute stereotyped, involuntary laughter with mirth preceding her usual migraine headaches, whose episode resolved with ubrogepant...She is currently on a preventive medication regimen including onabotulinumtoxinA, fremanezumab, acetazolamide, and lamotrigine... This is a rare presentation of gelastic migraine. In the absence of other identifiable etiology for the gelastic symptoms, we believe that this case describes an atypical temporal lobe aura, with the attack aborted by a gepant."

Clinical • CNS Disorders • Epilepsy • Migraine • Pain

Comparative efficacy of Symbravo® versus gepants for acute treatment of migraine: A network meta-analysis (AHS 2026) - "Background: Symbravo® (20 mg MoSEIC(TM) meloxicam and 10 mg rizatriptan [MxRz]) is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine approved for acute treatment of migraine with or without aura. The NMA favors MxRz over rimegepant, ubrogepant, and zavegepant for acute migraine. MxRz is particularly effective in achieving 2-h and 2–24 h sustained pain freedom, offering a promising therapeutic alternative for patients with inadequate response to prior treatments."

Retrospective data • CNS Disorders • Migraine • Pain